Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats.
Oxidative stress has been postulated to be involved in the development of diabetic nephropathy. In the present study, we evaluated the effect of taurine, an endogenous antioxidant, on diabetic nephropathy by mixing it with the daily drinking water (1%w/v) of streptozotocin-induced diabetic rats from the beginning of the fourth month after the induction of diabetes, during which the urinary protein excretion in untreated diabetic rats showed significant increase in comparison with nondiabetic rats. The taurine administration significantly suppressed further increase in urinary protein excretion in diabetic rats, accompanied by the reduction of mesangial extracellular matrix expansion and TGF-beta expression in the renal glomerulus. Immunohistochemical study showed that taurine administration suppressed the intensified stainings to the three different types of oxidative stress markers, such as 8-hydroxyl-2'-deoxyguanosine (8-OHdG), pentosidine, and nitrotyrosine observed in the renal tissues of untreated diabetic rats. These findings suggest that taurine has the ability to suppress the progression of diabetic nephropathy at least in part by its antioxidant property. Since this beneficial effect of taurine was obtained even if its administration was started after the time point when urinary protein excretion already became apparently higher than that of age-matched nondiabetic animals, taurine administration was potentially expected to be applied in clinical field to retard the development of nephropathy in diagnosed diabetic patients.
Higo
Satomi
S
Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyata
Satoshi
S
Jiang
Qing Yun
QY
Kitazawa
Riko
R
Kitazawa
Sohei
S
Kasuga
Masato
M
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D015415:Biomarkers; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology* / Q000652:urine; D018450:Disease Progression; D006442:Glycated Hemoglobin / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D018384:Oxidative Stress; D011507:Proteinuria / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013654:Taurine / Q000008:administration & dosage* / Q000627:therapeutic use*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism
D000080242:8-Hydroxy-2'-Deoxyguanosine; D015415:Biomarkers; D001786:Blood Glucose; D003849:Deoxyguanosine; D006442:Glycated Hemoglobin; D013654:Taurine; D014443:Tyrosine; C002744:3-nitrotyrosine